Literature DB >> 6307906

Ploidy as a prognostic factor in ovarian cancer.

M L Friedlander, I W Taylor, P Russell, E A Musgrove, D H Hedley, M H Tattersall.   

Abstract

The cellular DNA content of 50 ovarian common epithelial carcinomas was determined by flow cytometry, and tumours were classified as being either diploid or aneuploid. A significant association between tumour stage and ploidy was demonstrated, with all diploid tumours being of an early stage (p less than 0.001). Forty percent of early-stage tumours (FIGO stages I and II) and all late-stage tumours (FIGO stages III and IV) were aneuploid. This heterogeneity with respect to DNA content among tumours of a similar stage may allow the identification of neoplasms with a different natural history. The proportion of S-phase cells determined by flow cytometry is a measure of cellular proliferation and may also be of prognostic significance. Diploid tumours had a median S phase of 9.8% (2.4-14.1%), while aneuploid tumours had a significantly higher S phase of 19.6% (7-24.7%; p less than 0.05). In this study there was no relationship between histological grading of invasive carcinomas and ploidy, but in view of the relatively small numbers and limited follow-up, it was not possible to perform a multivariate analysis of all known prognostic factors in ovarian cancer. Our results suggest that ploidy reflects tumour behaviour, but prolonged follow-up and increased patient accrual is necessary to assess whether the flow cytometric analysis of DNA content will provide clinically important information in ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6307906     DOI: 10.1097/00004347-198301000-00005

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  10 in total

1.  Nuclear DNA content of borderline tumors of the ovary: correlation with histology and significance for prognosis.

Authors:  M Dietel; H Arps; A Rohlff; R Bodecker; A Niendorf
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

2.  Clinical DNA flow cytometry.

Authors:  B Tribukait
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

Review 3.  Clinical and biological significance of aneuploidy in human tumours.

Authors:  M L Friedlander; D W Hedley; I W Taylor
Journal:  J Clin Pathol       Date:  1984-09       Impact factor: 3.411

4.  Assessment of proliferative activity in ovarian neoplasms by flow and static cytometry. Correlation with prognostic features.

Authors:  P C Huettner; D S Weinberg; J M Lage
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

5.  Multivariate analyses of DNA index, p62c-myc, and clinicopathological status of patients with ovarian cancer.

Authors:  M Curling; S Stenning; C N Hudson; J V Watson
Journal:  J Clin Pathol       Date:  1998-06       Impact factor: 3.411

6.  DNA cytophotometry in malignant thyroid tumors--use of different evaluation schemes for prognostic statements.

Authors:  H Arps; B Sablotny; M Dietel; A Niendorf; S Schröder
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

7.  Tetraploid cells from cytokinesis failure induce aneuploidy and spontaneous transformation of mouse ovarian surface epithelial cells.

Authors:  Lei Lv; Tianwei Zhang; Qiyi Yi; Yun Huang; Zheng Wang; Heli Hou; Huan Zhang; Wei Zheng; Qiaomei Hao; Zongyou Guo; Howard J Cooke; Qinghua Shi
Journal:  Cell Cycle       Date:  2012-08-01       Impact factor: 4.534

8.  Ovarian tumour xenografts in the study of the biology of human epithelial ovarian cancer.

Authors:  M L Friedlander; P Russell; I W Taylor; M H Tattersall
Journal:  Br J Cancer       Date:  1985-03       Impact factor: 7.640

9.  Cellular DNA content--a stable feature in epithelial ovarian cancer.

Authors:  M L Friedlander; I W Taylor; P Russell; M H Tattersall
Journal:  Br J Cancer       Date:  1984-02       Impact factor: 7.640

10.  DNA index of ovarian carcinomas from 56 patients: in vivo in vitro studies.

Authors:  E Erba; M Vaghi; S Pepe; G Amato; M Bistolfi; P Ubezio; C Mangioni; F Landoni; L Morasca
Journal:  Br J Cancer       Date:  1985-10       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.